NCT01764854 - Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

End Stage Renal DiseaseChronic Kidney Disease Stage 5ESRD

Interventions

DRUG

AZD1722 (in-patient)

doses between 5 and 60 mg BID may be administered based on tolerability in a CPU setting

DRUG

Placebo (in-patient)

Placebo, size and color matched to experimental drug administered in a CPU

DRUG

AZD1722 (out-patient)

doses between 5 and 45 mg BID

DRUG

Placebo

Placebo, size and color matched to experimental drug

Trial Locations (3)

DaVita Clinical Research, Minneapolis

Denver Nephrology, Denver

Southwest Clinical Research Institute, Tempe